Proceeds to expand Contract Development and Manufacturing Organization (CDMO) capacity to deliver GMP adeno-associated viruses (AAV) product for clients by mid-2021 and to develop a proprietary ...
Partnership to Bolster Solid Biosciences’ Gene Therapy Pipeline, Including AAV Process Development, Scale Up and cGMP Manufacturing Services Forge will provide an adeno-associated viral (AAV) vector ...
Skylark Bio ("Skylark"), a clinical-stage biotechnology company developing targeted genetic medicines for hearing loss, and ...
Forge Biologics, (“Forge”), a leading manufacturer of gene therapies and member of the Ajinomoto Bio-Pharma Services group, today announced it has achieved My Green Lab® Certification, the global gold ...
BOSTON & SEATTLE & COLUMBUS, Ohio--(BUSINESS WIRE)--GentiBio, Inc., an emerging biotherapeutics company developing best-in-class engineered regulatory T cells programmed to treat autoimmune, ...
Innovative collaboration advances the development of novel gene therapies for patients by providing coordinated services across Forge’s leading AAV manufacturing capabilities and Labcorp’s scientific ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min Unlike many of its peers in the ...
To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Most of the leadership at startup Forge Biologics Inc. has ...
Oral and poster presentations highlight data from Forge’s FUEL™ AAV manufacturing platform and advancements in process characterization and late-phase manufacturing to support the growing number of ...
Forge Biologics, a gene therapy-focused contract development and manufacturing organization (CDMO), has launched the Forge Forward gene therapy workforce development program in partnership with the ...
Proceeds to expand Contract Development and Manufacturing Organization (CDMO) capacity to deliver GMP adeno-associated viruses (AAV) product for clients by mid-2021 and to develop a proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results